Log In
Print
BCIQ
Print
Print this Print this
 

TAK-733

  Manage Alerts
Collapse Summary General Information
Company Takeda Pharmaceutical Co. Ltd.
DescriptionMEK inhibitor
Molecular Target MAP kinase kinase 1 (MAP2K1) (MEK1) ; MAP kinase kinase 2 (MAP2K2) (MEK2)
Mechanism of ActionMEK inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat solid tumors
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today